Integral Health Asset Management’s Revolution Medicines RVMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$281M Hold
1,500,000
– – 11.1% 1
2026
Q1
$146M Buy
1,500,000
+300,000
+25% +$30.3M 6.98% 2
2025
Q4
$95.6M Buy
1,200,000
+800,000
+200% +$52.5M 4.75% 2
2025
Q3
$18.7M Buy
400,000
+75,000
+23% +$2.94M 1.26% 24
2025
Q2
$12M Buy
325,000
+75,000
+30% +$2.88M 1.09% 31
2025
Q1
$8.84M Sell
250,000
-300,000
-55% -$12.2M 0.94% 31
2024
Q4
$24.1M Buy
550,000
+200,000
+57% +$10.1M 2.05% 11
2024
Q3
$15.9M Buy
350,000
+25,000
+8% +$1.09M 1.79% 16
2024
Q2
$12.6M Sell
325,000
-95,000
-23% -$3.55M 1.2% 28
2024
Q1
$13.5M Buy
420,000
+220,000
+110% +$6.52M 1.26% 34
2023
Q4
$5.74M Sell
200,000
-325,000
-62% -$7.81M 0.78% 54
2023
Q3
$14.5M Buy
525,000
+169,000
+47% +$5.01M 2.01% 18
2023
Q2
$9.52M Buy
356,000
+11,000
+3% +$270K 1.18% 35
2023
Q1
$7.47M Buy
+345,000
New +$8.5M 1.51% 30

Other funds holding RVMD

Integral Health Asset Management's RVMD Position: Q2 2026 in Review

Integral Health Asset Management held its Revolution Medicines (RVMD) position steady in Q2 2026 at 1,500,000 shares worth $281M. The position accounts for 11.1% of the portfolio, ranked #1.

Integral Health Asset Management first reported a position in RVMD in Q1 2023 and has held it in 14 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Integral Health Asset Management held 1,500,000 shares of Revolution Medicines worth $281M as of Q2 2026.
  • Integral Health Asset Management left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 11.1% of Integral Health Asset Management's portfolio in Q2 2026, its #1 holding.
  • Integral Health Asset Management first reported a position in Revolution Medicines in Q1 2023 and has held it in 14 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.